Abstract
Objectives: The aim of the study was to compare between the effects of two most common iron chelating agents (Deferasirox and Deferoxamine) used in the management of beta-thalassemia major. Materials and Methods: A Cross section study conducted in Thalassemia and hereditary blood Diseases Center of Kut hospitals in September 2022, all the included patients were of \(\beta\)-thalassemia major type those treated with blood transfusion and iron chelating agents. Patients were divided into two groups. First group included 20 patients receiving Deferasirox (Exjade) Novartis Europharm Basil, Switzerland and another group included 20 patients receiving Deferoxamine (Desferal) Novartis Europharm Basil, Switzerland as iron chelating agents. Both of them manufactured from Novartis Europharm- Basil, Switzerland. Results: The results showed that serum ferritin levels were significantly lowered in Exjade group compared to deferoxamine group indicating that, Exjade was more effective in reducing iron overload compared to deferoxamine. There were no significant differences for other laboratory investigations between the chelating agent groups. Conclusion: our study indicated that exjade is more effective than deferoxamine in treatment of iron overload so should using of exjade lead to decrease effects of iron on vital organs and minimized mortality rate of thalassemia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
